The Global Point Of Care Testing Market was valued at USD 42 billion in 2024 and is estimated to grow at a CAGR of 7% to reach USD 82 billion by 2034.
The market’s expansion is driven by increasing disease prevalence in developing nations, the growing number of diagnostic laboratories equipped with advanced testing technologies, and significant investments in research and development. Rising demand for rapid, accurate diagnostics in emergency care and remote locations is pushing governments and healthcare organizations to adopt innovative POC testing solutions. Point-of-care testing enables clinicians to obtain fast, lab-grade results directly at the patient’s location, facilitating quick medical decisions and reducing dependence on central labs. Devices use advanced technologies such as microfluidic platforms, immunoassays, and lateral flow assays to analyze blood, urine, or saliva, often providing results within minutes. Modern devices often integrate with mobile apps or electronic health records, improving accessibility in rural and underserved areas.
The endocrinology testing products segment held a substantial share of 33.1% in 2024. This segment is growing steadily due to the increasing prevalence of endocrine disorders, including diabetes and thyroid-related conditions, which demand rapid and accurate diagnostics. Advances in biosensors, immunoassays, and microfluidic technology have improved test efficiency and accuracy. Devices like glucose meters and HbA1c analyzers are evolving into smart tools connected to mobile apps for remote monitoring and telehealth applications.
The lateral flow assays segment was valued at USD 9.3 billion in 2024. LFAs are paper-based diagnostic devices that detect target substances in liquid samples using antibodies. They are widely used due to their simplicity, speed, and ease of use. Rising incidences of infectious diseases have accelerated the demand for LFAs, which allow healthcare providers to quickly screen, diagnose, and respond to patients, supporting faster treatment decisions and better outcomes.
U.S. Point of Care Testing Market was valued at USD 12.5 billion in 2024. Growth is being driven by increasing disease prevalence, particularly diabetes, and the rising adoption of fast, technology-enabled diagnostic solutions. The U.S. healthcare sector’s focus on innovation and accessibility has positioned it as a leading market for point-of-care testing technologies.
Key players in the Global Point of Care Testing Market include Meridian Bioscience, Abbott Laboratories, Bio-Rad Laboratories, LifeScan IP Holdings, LLC, Acon Laboratories, Becton, Dickinson, and Company, Danaher Corporation, BioMerieux SA, Dexcom, Inc., QuidelOrtho Corporation, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd., Medtronic Plc, Nova Biomedical, Siemens Healthineers AG, and Sysmex Corporation. Companies in the Point of Care Testing Market are leveraging multiple strategies to strengthen their market presence. They are heavily investing in R&D to develop faster, more accurate, and connected diagnostic devices. Strategic collaborations, partnerships, and acquisitions allow firms to expand product portfolios and enter new regional markets. Many are focusing on technological innovation, integrating AI, connectivity, and digital health platforms into devices to improve data management and telemedicine capabilities.
This product will be delivered within 2-4 business days.
The market’s expansion is driven by increasing disease prevalence in developing nations, the growing number of diagnostic laboratories equipped with advanced testing technologies, and significant investments in research and development. Rising demand for rapid, accurate diagnostics in emergency care and remote locations is pushing governments and healthcare organizations to adopt innovative POC testing solutions. Point-of-care testing enables clinicians to obtain fast, lab-grade results directly at the patient’s location, facilitating quick medical decisions and reducing dependence on central labs. Devices use advanced technologies such as microfluidic platforms, immunoassays, and lateral flow assays to analyze blood, urine, or saliva, often providing results within minutes. Modern devices often integrate with mobile apps or electronic health records, improving accessibility in rural and underserved areas.
The endocrinology testing products segment held a substantial share of 33.1% in 2024. This segment is growing steadily due to the increasing prevalence of endocrine disorders, including diabetes and thyroid-related conditions, which demand rapid and accurate diagnostics. Advances in biosensors, immunoassays, and microfluidic technology have improved test efficiency and accuracy. Devices like glucose meters and HbA1c analyzers are evolving into smart tools connected to mobile apps for remote monitoring and telehealth applications.
The lateral flow assays segment was valued at USD 9.3 billion in 2024. LFAs are paper-based diagnostic devices that detect target substances in liquid samples using antibodies. They are widely used due to their simplicity, speed, and ease of use. Rising incidences of infectious diseases have accelerated the demand for LFAs, which allow healthcare providers to quickly screen, diagnose, and respond to patients, supporting faster treatment decisions and better outcomes.
U.S. Point of Care Testing Market was valued at USD 12.5 billion in 2024. Growth is being driven by increasing disease prevalence, particularly diabetes, and the rising adoption of fast, technology-enabled diagnostic solutions. The U.S. healthcare sector’s focus on innovation and accessibility has positioned it as a leading market for point-of-care testing technologies.
Key players in the Global Point of Care Testing Market include Meridian Bioscience, Abbott Laboratories, Bio-Rad Laboratories, LifeScan IP Holdings, LLC, Acon Laboratories, Becton, Dickinson, and Company, Danaher Corporation, BioMerieux SA, Dexcom, Inc., QuidelOrtho Corporation, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd., Medtronic Plc, Nova Biomedical, Siemens Healthineers AG, and Sysmex Corporation. Companies in the Point of Care Testing Market are leveraging multiple strategies to strengthen their market presence. They are heavily investing in R&D to develop faster, more accurate, and connected diagnostic devices. Strategic collaborations, partnerships, and acquisitions allow firms to expand product portfolios and enter new regional markets. Many are focusing on technological innovation, integrating AI, connectivity, and digital health platforms into devices to improve data management and telemedicine capabilities.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Bn)
Chapter 6 Market Estimates and Forecast, by Technology, 2021-2034 ($ Bn)
Chapter 7 Market Estimates and Forecast, by Application, 2021-2034 ($ Bn)
Chapter 8 Market Estimates and Forecast, by Prescription, 2021-2034 ($ Bn)
Chapter 9 Market Estimates and Forecast, by End Use, 2021-2034 ($ Bn)
Chapter 10 Market Estimates and Forecast, by Region, 2021-2034 ($ Bn)
Chapter 11 Company Profiles
Companies Mentioned
The companies profiled in this Point of Care Testing market report include:- Abbott Laboratories
- Acon Laboratories
- Becton, Dickinson, and Company
- BioMerieux SA
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Dexcom, Inc
- Drägerwerk AG & Co. KGaA
- F. Hoffmann-La Roche Ltd.
- LifeScan IP Holdings, LLC
- Medtronic Plc
- Meridian Bioscience, Inc.
- Nova Biomedical
- QuidelOrtho Corporation
- Siemens Healthineers AG
- Sysmex Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 163 |
| Published | October 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 42 Billion |
| Forecasted Market Value ( USD | $ 82 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
